Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,749	198 Pages	360iResearch	January, 2024	IRE18449407

Best Price Guarantee
Price	from $4,749
Length	198 Pages
Publisher	360iResearch
Published Date	January, 2024
SKU	IRE18449407

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2024-2030

The Prostate Cancer Diagnostics Market size was estimated atUSD 1.27 billion in 2023and expected to reachUSD 1.45 billion in 2024,at aCAGR 14.20%to reachUSD 3.23 billion by 2030.

Global Prostate Cancer Diagnostics Market

Note: PDF & Excel + Online Access - 1 Year

1. Preface: 1.1. Objectives of the Study; 1.2. Market Segmentation & Coverage; 1.3. Years Considered for the Study; 1.4. Currency & Pricing; 1.5. Language; 1.6. Limitations; 1.7. Assumptions; 1.8. Stakeholders
2. Research Methodology: 2.1. Define: Research Objective; 2.2. Determine: Research Design; 2.3. Prepare: Research Instrument; 2.4. Collect: Data Source; 2.5. Analyze: Data Interpretation; 2.6. Formulate: Data Verification; 2.7. Publish: Research Report; 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview: 4.1. Introduction; 4.2. Prostate Cancer Diagnostics Market, by Region
5. Market Insights: 5.1. Market Dynamics; 5.1.1. Drivers; 5.1.1.1. Rising aging population and increasing prevalence rate of prostate cancer; 5.1.1.2. Growing government’s initiatives for advancement in technology in diagnosis and creating awareness regarding cancer; 5.1.2. Restraints; 5.1.2.1. Stringent regulations and high cost of diagnosis; 5.1.3. Opportunities; 5.1.3.1. Innovation in drugs and developments in genomics and proteomics; 5.1.3.2. Imaging research and advancements for accurate detection of prostate cancer; 5.1.4. Challenges; 5.1.4.1. Low success rate of clinical trials; 5.2. Market Segmentation Analysis; 5.3. Market Trend Analysis; 5.4. Cumulative Impact of High Inflation; 5.5. Porter’s Five Forces Analysis; 5.5.1. Threat of New Entrants; 5.5.2. Threat of Substitutes; 5.5.3. Bargaining Power of Customers; 5.5.4. Bargaining Power of Suppliers; 5.5.5. Industry Rivalry; 5.6. Value Chain & Critical Path Analysis; 5.7. Regulatory Framework
6. Prostate Cancer Diagnostics Market, by Test Type: 6.1. Introduction; 6.2. Confirmatory Tests; 6.3.1. Biopsy; 6.3.2. PCA3 Tests; 6.3.3. Trans-Rectal Ultrasound; 6.3. Preliminary Tests
7. Prostate Cancer Diagnostics Market, by Age Group: 7.1. Introduction; 7.2. Age 55-75; 7.3. Age <55; 7.4. Age>75
8. Prostate Cancer Diagnostics Market, by End-User: 8.1. Introduction; 8.2. Cancer Research Institutes; 8.3. Hospital Associated Laboratories; 8.4. Independent Diagnostic Laboratories
9. Americas Prostate Cancer Diagnostics Market: 9.1. Introduction; 9.2. Argentina; 9.3. Brazil; 9.4. Canada; 9.5. Mexico; 9.6. United States
10. Asia-Pacific Prostate Cancer Diagnostics Market: 10.1. Introduction; 10.2. Australia; 10.3. China; 10.4. India; 10.5. Indonesia; 10.6. Japan; 10.7. Malaysia; 10.8. Philippines; 10.9. Singapore; 10.10. South Korea; 10.11. Taiwan; 10.12. Thailand; 10.13. Vietnam
11. Europe, Middle East & Africa Prostate Cancer Diagnostics Market: 11.1. Introduction; 11.2. Denmark; 11.3. Egypt; 11.4. Finland; 11.5. France; 11.6. Germany; 11.7. Israel; 11.8. Italy; 11.9. Netherlands; 11.10. Nigeria; 11.11. Norway; 11.12. Poland; 11.13. Qatar; 11.14. Russia; 11.15. Saudi Arabia; 11.16. South Africa; 11.17. Spain; 11.18. Sweden; 11.19. Switzerland; 11.20. Turkey; 11.21. United Arab Emirates; 11.22. United Kingdom
12. Competitive Landscape: 12.1. FPNV Positioning Matrix; 12.2. Market Share Analysis, By Key Player; 12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio: 13.1. Key Company Profiles; 13.1.1. AdvaCare Pharma; 13.1.2. bioMérieux SA; 13.1.3. Eurolyser Diagnostica; 13.1.4. Exact Sciences Corporation; 13.1.5. F. Hoffmann-La Roche AG; 13.1.6. Hologic, Inc.; 13.1.7. Koninklijke Philips N.V.; 13.1.8. mdxhealth BV; 13.1.9. Myriad Genetics, Inc.; 13.1.10. OPKO Health, Inc.; 13.1.11. Prostatype Genomics AB; 13.1.12. Proteomedix AG; 13.1.13. Siemens Healthineers AG; 13.2. Key Product Portfolio
14. Appendix: 14.1. Discussion Guide; 14.2. License & Pricing; FIGURE 1. PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH PROCESS; FIGURE 2. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030; FIGURE 3. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION); FIGURE 4. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%); FIGURE 5. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 6. PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS; FIGURE 7. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%); FIGURE 8. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 9. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%); FIGURE 10. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 11. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%); FIGURE 12. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 13. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 14. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 15. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%); FIGURE 16. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 17. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 18. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 21. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023; FIGURE 22. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

Prostate Cancer Diagnostics Market Report by Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Others), Test Type (Preliminary Tests, Confirmatory Tests), End User (Hospitals, Diagnostic Centers, Research Institutes, and Others), Regions, and Company Analysis 2024-2032

June, 2024 | Published by: Renub Research | USD $2,790
Prostate Cancer Diagnostics Market Forecasts to 2030 – Global Analysis By Test Type (Preliminary Tests, Confirmatory Tests, Immunohistochemistry and Other Test Types), Cancer Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma and Other Cancer Types), End User (Hospitals, Outpatient Facilities, Diagnostic Laboratories, Cancer Research Institutes, Home Care, Research & Manufacturing and Other End Users) and by Geography

January, 2024 | Published by: Stratistics Market Research Consulting | USD $4,150
Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use, By Region, And Segment Forecasts, 2024 - 2030

December, 2023 | Published by: Grand View Research | USD $5,950
Prostate Cancer Diagnostics Global Market Report 2023 Including: 1) By Products: Instruments; Reagents And Consumables; Accessories 2) By Test Type: Preliminary Tests; Confirmatory Tests 3) By Prostate Cancer: Squamous Cell Cancer; Small Cell Carcinoma; Transitional Cell Cancer; Prostatic Adenocarcinoma; Ductal Adenocarcinoma; Small Cell Prostate Cancer; Acinar Adenocarcinoma 4) By Peer Groups: Adult; Pediatric; Geriatrics 5) By End User: Hospitals; Independent Diagnostic Laboratories; Cancer Research Institutess Covering: F. Hoffman-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG

September, 2023 | Published by: The Business Research Company | USD $5,000
Prostate-Specific Antigen Test Market - By Test Type (Preliminary {Total, Complex, Free}, Confirmatory {PCA3, Biopsy}), By Application (Screening, Monitoring), By End-use (Hospitals, Specialty Clinics, Diagnostic Centers) - Global Forecast, 2023-2032

October, 2023 | Published by: Global Market Insights | USD $5,150
Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial cell carcinoma, Others), By End use (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2019-2029F

May, 2024 | Published by: TechSci Research | USD $4,900

PDF E-mail From Publisher:	$4,749
PDF E-mail From Publisher (2-5)Users License:	$5,749
Site License:	$6,749
Global Site License Fulfilled by Publisher:	$8,749

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2024-2030

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2024-2030

Research Assistance

Other tasks

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2024-2030

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2024-2030

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial Cell Carcinoma, Other), By End Use, By Region, And Segment Forecasts, 2024 - 2030

Prostate-Specific Antigen Test Market - By Test Type (Preliminary {Total, Complex, Free}, Confirmatory {PCA3, Biopsy}), By Application (Screening, Monitoring), By End-use (Hospitals, Specialty Clinics, Diagnostic Centers) - Global Forecast, 2023-2032

Research Assistance

Other tasks